Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "STAR-221 Phase 3 Trial - Domvanalimab, Zimberelimab, & Chemo vs. Nivo & Chemo in Previously Untreated, Locally Advanced, Unresectable or Metastatic GC/GEJC/EC"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Samuel Klempner
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Samuel Klempner
Login to view comments.
Click here to Login